Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 193,02 € (+22,44 %). Medianen er 193,02 € (+22,44 %).
| Køb |
6 |
| Behold |
4 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Balchem beats Q1 expectations and records 27th consecutive quarter of EBITDA growth
Balchem reported adjusted EPS of $1.33 for Q1 2026 (consensus $1.25) and revenue of $270.7 million (consensus $265.8 million). Adjusted EBITDA rose 12.1% to $74.3 million with a margin of 27.4%, marking the company’s 27th consecutive quarter of EBITDA growth. Despite strong metrics, the stock fell about 2% premarket, partly due to profit-taking near the 52-week high. Management emphasizes robust cash flow, low net leverage (net debt/EBITDA 0.3x) and strategic growth initiatives, but sees risks from commodity inflation and currency fluctuations. » Mere på de.investing.com
Balchem beats Q1 expectations with stronger margin, stock slips in premarket
Balchem reported adjusted EPS of $1.33 for Q1 2026 (forecast $1.25) and revenue of $271 million (expectation $265.8 million), with both metrics topping analyst estimates. Gross margin rose 210 basis points to 37.3% and adjusted EBITDA grew 12.1%, marking the company’s 27th consecutive quarter of EBITDA growth. Despite the results, the stock fell about 2% premarket; management pointed to operational efficiency, pricing strategies and an optimistic outlook with expected further revenue gains. » Mere på de.investing.com
Balchem achieves over 1 billion USD in revenue for first time in 2025, quarterly profit beats expectations
Balchem reported adjusted EPS of $1.31 for Q4 2025 versus $1.18 expected, and revenue of $263.6 million, slightly above consensus. For fiscal 2025, consolidated revenue was $1,037.2 million (+8.8%), adjusted EBITDA was $274.9 million and adjusted net income was $167.9 million, with margins expanding to 26.5%. Net debt fell to 0.3x EBITDA, free cash flow increased significantly, and the annual dividend was raised by 10% to $0.96. Management remains cautiously optimistic for 2026, sees growth potential from international expansion, product innovation and targeted M&A, but cautions about input-cost and macroeconomic risks. » Mere på de.investing.com
Balchem focuses on growth at the intersection of nutrition, health and pharma
CEO Ted Harris emphasizes strong demand across all end markets and the company’s strategic positioning at the convergence of food, nutrition and pharma. Balchem is concentrating on scaling in growth segments, innovation and targeted M&A, pursuing strict margin and cash‑flow management as well as a capital allocation policy that includes dividend increases and share buybacks. Microencapsulation capacity is planned to double by the end of 2027/2028; the company expects revenues of around $5.161 billion (2025) and $5.399 billion (2026). Sustainability progress is significant, while risks include EU anti‑dumping duties on Chinese choline and potential supply‑chain disruptions. » Mere på de.investing.com
Balchem significantly exceeds earnings expectations in the second quarter of 2025
In the second quarter of 2025, Balchem surpassed analyst expectations for both revenue and earnings per share, achieving record results. The company benefited from strong demand, innovation, and efficiency improvements, leading to a 9.1% increase in revenue and a 19.4% rise in profit. The stock responded with a slight uptick, while management provided a positive outlook for continued growth. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 256,61 mio. | 12,55 % |
| Bruttofortjeneste | 93,33 mio. | 14,74 % |
| Nettoresultat | 41,25 mio. | 20,16 % |
| EBITDA | 63,95 mio. | 13,79 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 5,01 mia. € |
Antal aktier | 31,88 mio. |
Højeste/laveste i 52 uger | 169,09 € - 133,69 € |
Udbytteafkast | 0,52 % |
Udbytte TTM | 0,82 € |
Beta | 0,85 |
P/E (PE Ratio) | 32,42 |
PEG (PEG Ratio) | 2,02 |
K/I (PB Ratio) | 4,18 |
P/S (PS Ratio) | 4,98 |
Virksomhedsprofil
Balchem Corporation udvikler, fremstiller og markedsfører specialiserede ydelsesingredienser og produkter til ernærings-, fødevare-, farmaceutiske, dyresundhedsmæssige, medicinske sterilisationsudstyr-, plantenæringsmæssige og industrielle markeder i USA og internationalt. Virksomheden opererer gennem tre segmenter: Human Nutrition & Health, Animal Nutrition & Health og Specialty Products. Segmentet Human Nutrition & Health leverer ingredienser til fødevare- og drikkevareindustrien. Dets produkter omfatter spray-tørrede og emulgerede pulvere, ekstrusion og agglomerering, blandede lipidsystemer, flydende smagsleveringssystemer, juice- og mælkebaser, chokoladesystemer og cerealiesystemer samt isbaser og variegater. Segmentet tilbyder desuden mikroindkapslingsløsninger til forskellige anvendelser og choline-næringsstoffer i humankvalitet samt mineralaminosyrechelaterede produkter til ernærings- og sundhedsformål. Segmentet Animal Nutrition & Health leverer mikroindkapslede produkter, der fremmer sundhed og mælkeproduktion, og som leverer næringstilskud til drøvtyggere; chelateringsteknologi, der giver forbedret næringsoptagelse hos forskellige produktions- og husdyrarter; samt cholinchlorid, et næringsstof til monogastriske dyrs sundhed. Segmentet Specialty Products tilbyder ethylenoxid, primært til brug i sundhedssektoren, og engangsbeholdere med ethylenoxid til sterilisering af genanvendelige medicinsk udstyr. Segmentet markedsfører og sælger desuden propylenoxid, et begasningsmiddel til bekæmpelse af insekter og mikrobiologisk fordærvelse samt til reduktion af bakterie- og skimmelsvampforurening i skallede og forarbejdede nødder, forarbejdede krydderier, kakaobønner, kakaopulver, rosiner, figner og svesker; og chelaterede mineraler til højværdiafgrøder. Virksomheden sælger sine produkter gennem en salgsstyrke, uafhængige distributører og salgsagenter. Balchem Corporation blev stiftet i 1967 og har hovedkontor i New Hampton, New York.
| Navn | Balchem Co. |
| CEO | Theodore L. Harris |
| Hjemsted | Montvale,
nj USA |
| Websted | |
| Sektor | Dagligvarer |
| Branche | Fødevarer |
| Børsnotering | 03.06.1986 |
| Medarbejdere | 1.430 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | BCPC |
Frankfurt | BL9B.F |
Düsseldorf | BL9B.DU |
SIX | BL9B.SW |
München | BL9B.MU |